Article info

Download PDFPDF
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Authors

  1. Correspondence to Dr Yusuf Ilhan, Department of Medical Oncology, Akdeniz University, Antalya, Turkey; dryusufilhan{at}gmail.com
View Full Text

Citation

Ilhan Y, Tatli AM, Teker F, et al
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Publication history

  • Received October 4, 2021
  • Accepted January 13, 2022
  • First published January 27, 2022.
Online issue publication 
June 01, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.